Ontology type: schema:ScholarlyArticle
2015-03-11
AUTHORSTomoya Muto, Masahiro Takeuchi, Atsuko Yamazaki, Yasumasa Sugita, Shokichi Tsukamoto, Shio Sakai, Yusuke Takeda, Naoya Mimura, Chikako Ohwada, Emiko Sakaida, Nobuyuki Aotsuka, Tohru Iseki, Chiaki Nakaseko
ABSTRACTAcute myeloid leukemia (AML) with mixed lineage leukemia-eleven-nineteen lysine-rich leukemia (MLL-ELL) is a rare subtype of MLL-rearranged AML. The outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with this disease remains unknown. In the present study, we retrospectively investigated the efficacy of allo-HSCT in eight adult MLL-ELL-positive AML patients. Although all eight patients achieved first complete remission (CR1), three (37.5 %) patients experienced relapse after induction therapy. Five (62.5 %) patients underwent allo-HSCT during CR1, whereas two (25.0 %) underwent allo-HSCT during disease relapse, and one (12.5 %) during CR2. All three patients who received allo-HSCT beyond CR1 died due to AML progression after allo-HSCT. Of the five patients who received allo-HSCT during CR1, three (60.0 %) remained alive at study conclusion. The overall survival rate at five years was 50.0 %. Intriguingly, clonally expanded non-leukemic cells expressing MLL-ELL during consolidation therapy were found to be eradicated after allo-HSCT during the monitoring of minimal residual disease in one patient; this indicates that allo-HSCT is efficacious for eliminating pre-leukemic cells resistant to chemotherapy. In conclusion, allo-HSCT soon after CR1 represents a promising therapeutic option for adult AML patients with MLL-ELL, although the outcome of allo-HSCT for patients beyond CR1 was dismal. More... »
PAGES86-92
http://scigraph.springernature.com/pub.10.1007/s12185-015-1779-z
DOIhttp://dx.doi.org/10.1007/s12185-015-1779-z
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1016907991
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/25758097
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adolescent",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Chromosome Breakage",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease Progression",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Graft vs Host Disease",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hematopoietic Stem Cell Transplantation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukemia, Myeloid, Acute",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Myeloid-Lymphoid Leukemia Protein",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasm, Residual",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Oncogene Proteins, Fusion",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Reverse Transcriptase Polymerase Chain Reaction",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Transplantation Conditioning",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Transplantation, Homologous",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Young Adult",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Muto",
"givenName": "Tomoya",
"id": "sg:person.01301502762.31",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301502762.31"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Takeuchi",
"givenName": "Masahiro",
"id": "sg:person.01051540664.64",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051540664.64"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Yamazaki",
"givenName": "Atsuko",
"id": "sg:person.0722141221.31",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722141221.31"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Sugita",
"givenName": "Yasumasa",
"id": "sg:person.0654026021.42",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654026021.42"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Tsukamoto",
"givenName": "Shokichi",
"id": "sg:person.01146755121.17",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146755121.17"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Sakai",
"givenName": "Shio",
"id": "sg:person.01265260514.92",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265260514.92"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Takeda",
"givenName": "Yusuke",
"id": "sg:person.01236704357.87",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236704357.87"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Mimura",
"givenName": "Naoya",
"id": "sg:person.01315773033.32",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315773033.32"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Ohwada",
"givenName": "Chikako",
"id": "sg:person.01024202356.59",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024202356.59"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Sakaida",
"givenName": "Emiko",
"id": "sg:person.0775302360.96",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775302360.96"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Hematology-Oncology, Japanese Red Cross Society Narita Hospital, Narita, Japan",
"id": "http://www.grid.ac/institutes/grid.459661.9",
"name": [
"Division of Hematology-Oncology, Japanese Red Cross Society Narita Hospital, Narita, Japan"
],
"type": "Organization"
},
"familyName": "Aotsuka",
"givenName": "Nobuyuki",
"id": "sg:person.0577376767.42",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577376767.42"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Iseki",
"givenName": "Tohru",
"id": "sg:person.01177054671.93",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177054671.93"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan",
"id": "http://www.grid.ac/institutes/grid.411321.4",
"name": [
"Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan"
],
"type": "Organization"
},
"familyName": "Nakaseko",
"givenName": "Chiaki",
"id": "sg:person.01364756342.26",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364756342.26"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/sj.leu.2404954",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1049247283",
"https://doi.org/10.1038/sj.leu.2404954"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1532/ijh97.05025",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019192670",
"https://doi.org/10.1532/ijh97.05025"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf02982114",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1040986861",
"https://doi.org/10.1007/bf02982114"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12185-013-1407-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017088541",
"https://doi.org/10.1007/s12185-013-1407-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12185-012-1180-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1004914887",
"https://doi.org/10.1007/s12185-012-1180-0"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2012.319",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1004498635",
"https://doi.org/10.1038/leu.2012.319"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12185-008-0034-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1043046223",
"https://doi.org/10.1007/s12185-008-0034-2"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2013.135",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023532190",
"https://doi.org/10.1038/leu.2013.135"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nature13038",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015493548",
"https://doi.org/10.1038/nature13038"
],
"type": "CreativeWork"
}
],
"datePublished": "2015-03-11",
"datePublishedReg": "2015-03-11",
"description": "Acute myeloid leukemia (AML) with mixed lineage leukemia-eleven-nineteen lysine-rich leukemia (MLL-ELL) is a rare subtype of MLL-rearranged AML. The outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with this disease remains unknown. In the present study, we retrospectively investigated the efficacy of allo-HSCT in eight adult MLL-ELL-positive AML patients. Although all eight patients achieved first complete remission (CR1), three (37.5\u00a0%) patients experienced relapse after induction therapy. Five (62.5\u00a0%) patients underwent allo-HSCT during CR1, whereas two (25.0\u00a0%) underwent allo-HSCT during disease relapse, and one (12.5\u00a0%) during CR2. All three patients who received allo-HSCT beyond CR1 died due to AML progression after allo-HSCT. Of the five patients who received allo-HSCT during CR1, three (60.0\u00a0%) remained alive at study conclusion. The overall survival rate at five years was 50.0\u00a0%. Intriguingly, clonally expanded non-leukemic cells expressing MLL-ELL during consolidation therapy were found to be eradicated after allo-HSCT during the monitoring of minimal residual disease in one patient; this indicates that allo-HSCT is efficacious for eliminating pre-leukemic cells resistant to chemotherapy. In conclusion, allo-HSCT soon after CR1 represents a promising therapeutic option for adult AML patients with MLL-ELL, although the outcome of allo-HSCT for patients beyond CR1 was dismal.",
"genre": "article",
"id": "sg:pub.10.1007/s12185-015-1779-z",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1076985",
"issn": [
"0925-5710",
"1865-3774"
],
"name": "International Journal of Hematology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "102"
}
],
"keywords": [
"acute myeloid leukemia",
"allogeneic hematopoietic stem cell transplantation",
"hematopoietic stem cell transplantation",
"allo-HSCT",
"stem cell transplantation",
"AML patients",
"cell transplantation",
"myeloid leukemia",
"myeloablative allogeneic hematopoietic stem cell transplantation",
"positive acute myeloid leukemia",
"MLL-ELL",
"first complete remission",
"underwent allo-HSCT",
"adult AML patients",
"overall survival rate",
"positive AML patients",
"promising therapeutic option",
"minimal residual disease",
"pre-leukemic cells",
"non-leukemic cells",
"complete remission",
"induction therapy",
"consolidation therapy",
"adult patients",
"disease relapse",
"residual disease",
"therapeutic options",
"rare subtype",
"AML progression",
"patients",
"survival rate",
"leukemia",
"relapse",
"CR1",
"transplantation",
"therapy",
"disease",
"efficacy",
"present study",
"outcomes",
"study conclusions",
"conclusion",
"remission",
"cells",
"chemotherapy",
"subtypes",
"progression",
"lysine-rich leukemia",
"options",
"MLL",
"years",
"study",
"rate",
"monitoring",
"CR2"
],
"name": "Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia",
"pagination": "86-92",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1016907991"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s12185-015-1779-z"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"25758097"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s12185-015-1779-z",
"https://app.dimensions.ai/details/publication/pub.1016907991"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:02",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_651.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s12185-015-1779-z"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-015-1779-z'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-015-1779-z'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-015-1779-z'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-015-1779-z'
This table displays all metadata directly associated to this object as RDF triples.
313 TRIPLES
21 PREDICATES
107 URIs
90 LITERALS
25 BLANK NODES